CD8 Technology Services LLC signs letter of intent with Tevogen Bio for in-house manufacturing

From GlobeNewswire: 2025-04-30 15:49:00

Tevogen Bio Holdings Inc. announced a letter of intent with CD8 Technology Services LLC for a facility to support Tevogen’s cell therapy manufacturing. Tevogen Founder and CEO emphasized the importance of in-house manufacturing for operational efficiency. The press release also included forward-looking statements regarding Tevogen’s research and manufacturing capabilities, potential benefits of the agreement with CD8, and expectations for future product revenues. Factors that could impact the company’s performance include the need for additional capital, changes in market competition, economic conditions, and regulatory challenges. Tevogen emphasized the importance of not placing undue reliance on forward-looking statements. Contact Tevogen Bio Communications for more information.



Read more at GlobeNewswire: CD8 Technology Signs Letter of Intent for Tevogen Bio’s